Edition:
United States

People: Pacira Pharmaceuticals Inc (PCRX.O)

PCRX.O on Nasdaq

36.55USD
10:19am EDT
Change (% chg)

$-0.35 (-0.95%)
Prev Close
$36.90
Open
$36.84
Day's High
$37.50
Day's Low
$36.55
Volume
43,636
Avg. Vol
847,183
52-wk High
$80.25
52-wk Low
$31.08

Scibetta, James 

Mr. James S. Scibetta has been President of the Company. He is no longer Chief Financial Officer of the Company., effective May 3, 2016. He was Senior Vice President, Head of Technical Operations of the Company. James Scibetta has served as our chief financial officer since August 2008 and was named senior vice president in 2014. He has also served as our head of technical operations since January 2015. Mr. Scibetta currently oversees finance and other support services, as well as manufacturing and research and development activities at our Science Center campus in San Diego, California. Prior to his employment at Pacira, Mr. Scibetta was chief financial officer of Bioenvision, Inc. (NASDAQ: BIVN) from 2006 until its acquisition by Genzyme, Inc. in 2007. From 2001 to 2006, Mr. Scibetta was executive vice president and chief financial officer of Merrimack Pharmaceuticals, Inc. Mr. Scibetta formerly served as a senior investment banker at Shattuck Hammond Partners, LLC and PaineWebber Inc., providing capital acquisition, merger and acquisition, and strategic advisory services to healthcare companies. He currently serves on the board and chairs the audit committee of Matinas BioPharma, and previously served on the boards of Merrimack Pharmaceuticals, LaboPharm and Nephros. Mr. Scibetta holds a B.S. in physics from Wake Forest University, and an M.B.A. in finance from the University of Michigan. He completed executive education studies in the Harvard Business School Leadership & Strategy in Pharmaceuticals and Biotechnology program. Mr. Scibetta was named 2013 CFO of the Year by NJbiz.com.

Basic Compensation

Total Annual Compensation, USD 534,253
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,981,060
Fiscal Year Total, USD 3,515,320

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 40,000 1,523,830.00